# US 2005/0233341 A1 · Methods for identifying risk of melanoma and treatments thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0233341 A1
- Document ID: US20050233341A1
- Status: Published application
- Kind: A1
- Application number: 10/840,590
- Filed: 2004-05-05
- Published: 2005-10-20
- Earliest claimed: 2003-07-23
- Inventors: Richard Roth; Matthew Nelson; Stefan Kammerer; Andreas Braun; Carolyn Hoyal-Wrightson
- Web page: https://patentgrep.com/patent/US20050233341A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/172: Haplotypes
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are methods for identifying risk of melanoma in a subject and/or subjects at risk of melanoma, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating melanoma, therapeutic methods for treating melanoma in a subject and compositions comprising one or more melanoma cells and one or more NRP1, NID2, ENDO180, CDK10, FPGT, CARK, PCLO or REPS2 directed agents. These embodiments are based upon an analysis of polymorphic variations in a NRP1, NID2, ENDO180, CDK10, FPGT, CARK, PCLO or REPS2 nucleic acid, exemplified by nucleotide sequences of SEQ ID NO: 1-17.

## Claims

### Claim 1

A method for identifying a subject at risk of melanoma, which comprises detecting the presence or absence of a polymorphic variation associated with melanoma at one or more positions selected from the group consisting of rs6481845, rs10643659, rs7475391, rs7475394, rs7475396, rs9418057, rs5784335, rs2429390, rs7209331, rs4968706, rs8072984, rs9896444, rs4968617, rs7350907, rs8072519, rs6467914, rs3064869, rs10555175, rs6956848, position 63624 in SEQ ID NO: 6, position 65039 in SEQ ID NO: 6, rs489941, rs496008, rs4650251, rs531412, rs3765654, rs6660350, position 206 in SEQ ID NO: 5, rs5924619, rs5924564, rs4828523, rs5924569, rs2052763, rs1549529, rs5924573, rs4240072, rs5924580, rs4828544, rs5969758, rs1965051, rs1426800, rs1365529, rs5924545, rs5969761, rs6629202, rs5924584, rs1365530, rs6527769, rs2382813, rs2033120, rs2162394, rs1346246, rs1365527, rs4828524, rs5924588, rs5969764, rs5924589, rs5924590, rs5924593, rs4828547, rs5969768, rs4828526, rs5924595, rs5924549, rs5969769, rs4007744, rs2891073, rs5924599, rs1549531, rs5924601, rs5901609, rs5969739, rs5924602, rs1426798, rs4828550, rs5924603, rs1807947, rs2382814, rs5924606 and position 25216 in SEQ ID NO: 7;
whereby the presence of the one or more polymorphic variations is indicative of the subject being at risk of melanoma.

### Claim 2 (depends on 1)

The method of claim 1, which further comprises obtaining the nucleic acid sample from the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein a polymorphic variation is detected at one or more positions selected from the group consisting of rs6481845, rs10643659, rs7475391, rs7475394, rs7475396, rs9418057 and rs5784335.

### Claim 4 (depends on 1)

The method of claim 1, wherein a polymorphic variation is detected at one or more positions selected from the group consisting of rs2429390, rs7209331, rs4968706, rs8072984, rs9896444, rs4968617, rs7350907 and rs8072519.

### Claim 5 (depends on 1)

The method of claim 1, wherein a polymorphic variation is detected at one or more positions selected from the group consisting of rs6467914, rs3064869, rs10555175, rs6956848, position 63624 in SEQ ID NO: 6 and position 65039 in SEQ ID NO: 6.

### Claim 6 (depends on 1)

The method of claim 1, wherein a polymorphic variation is detected at one or more positions selected from the group consisting of rs489941, rs496008, rs4650251, rs531412, rs3765654, rs6660350 and position 206 in SEQ ID NO: 5.

### Claim 7 (depends on 1)

The method of claim 1, wherein a polymorphic variation is detected at one or more positions selected from the group consisting of rs5924619, rs5924564, rs4828523, rs5924569, rs2052763, rs1549529, rs5924573, rs4240072, rs5924580, rs4828544, rs5969758, rs1965051, rs1426800, rs1365529, rs5924545, rs5969761, rs6629202, rs5924584, rs1365530, rs6527769, rs2382813, rs2033120, rs2162394, rs1346246, rs1365527, rs4828524, rs5924588, rs5969764, rs5924589, rs5924590, rs5924593, rs4828547, rs5969768, rs4828526, rs5924595, rs5924549, rs5969769, rs4007744, rs2891073, rs5924599, rs1549531, rs5924601, rs5901609, rs5969739, rs5924602, rs1426798, rs4828550, rs5924603, rs1807947, rs2382814, rs5924606 and position 25216 in SEQ ID NO: 7.

### Claim 8 (depends on 1)

The method of claim 1, wherein one or more polymorphic variations are detected at one or more positions in linkage disequilibrium with a polymorphic variation at one or more of the positions in claim 1.

### Claim 9 (depends on 1)

The method of claim 1, wherein detecting the presence or absence of the one or more polymorphic variations comprises:
hybridizing an oligonucleotide to the nucleic acid sample, wherein the oligonucleotide is complementary to a nucleotide sequence in the nucleic acid and hybridizes to a region adjacent to the polymorphic variation;
extending the oligonucleotide in the presence of one or more nucleotides, yielding extension products; and
detecting the presence or absence of a polymorphic variation in the extension products.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 11

A method for identifying a polymorphic variation associated with melanoma proximal to an incident polymorphic variation associated with melanoma, which comprises:
identifying a polymorphic variation proximal to the incident polymorphic variation associated with melanoma, wherein the incident polymorphic variation is at a position selected from the group consisting of rs6481845, rs10643659, rs7475391, rs7475394, rs7475396, rs9418057, rs5784335, rs2429390, rs7209331, rs4968706, rs8072984, rs9896444, rs4968617, rs7350907, rs8072519, rs6467914, rs3064869, rs10555175, rs6956848, position 63624 in SEQ ID NO: 6, position 65039 in SEQ ID NO: 6, rs489941, rs496008, rs4650251, rs531412, rs3765654, rs6660350, position 206 in SEQ ID NO: 5, rs5924619, rs5924564, rs4828523, rs5924569, rs2052763, rs1549529, rs5924573, rs4240072, rs5924580, rs4828544, rs5969758, rs1965051, rs1426800, rs1365529, rs5924545, rs5969761, rs6629202, rs5924584, rs1365530, rs6527769, rs2382813, rs2033120, rs2162394, rs1346246, rs1365527, rs4828524, rs5924588, rs5969764, rs5924589, rs5924590, rs5924593, rs4828547, rs5969768, rs4828526, rs5924595, rs5924549, rs5969769, rs4007744, rs2891073, rs5924599, rs1549531, rs5924601, rs5901609, rs5969739, rs5924602, rs1426798, rs4828550, rs5924603, rs1807947, rs2382814, rs5924606 and position 25216 in SEQ ID NO: 7; and
determining the presence or absence of an association of the proximal polymorphic variant with melanoma.

### Claim 12 (depends on 11)

The method of claim 11, wherein the proximal polymorphic variation is within a region between about 5 kb 5′ of the incident polymorphic variation and about 5 kb 3′ of the incident polymorphic variation.

### Claim 13 (depends on 11)

The method of claim 11, which further comprises determining whether the proximal polymorphic variation is at a position in linkage disequilibrium with the incident polymorphic variation.

### Claim 14 (depends on 11)

The method of claim 11, which further comprises identifying a second polymorphic variation proximal to the identified proximal polymorphic variation associated with melanoma and determining if the second proximal polymorphic variation is associated with melanoma.

### Claim 15 (depends on 14)

The method of claim 14, wherein the second proximal polymorphic variant is within a region between about 5 kb 5′ of the incident polymorphic variation and about 5 kb 3′ of the proximal polymorphic variation associated with melanoma.

### Claim 16

An isolated nucleic acid which comprises a portion of or all of a nucleotide sequence in SEQ ID NO: 3, 4, 5, 6 and/or 7 and comprises one or more polymorphic variations selected from the group consisting of an adenine at position 16727 in SEQ ID NO: 3, a guanine at position 36589 in SEQ ID NO: 4, a thymine at position 44544 in SEQ ID NO: 4, a guanine at position 48304 in SEQ ID NO: 4, a guanine at position 53843 in SEQ ID NO: 6, a guanine at position 63624 in SEQ ID NO: 6, an adenine-thymine deletion at position 65039 in SEQ ID NO: 6, a guanine at position 206 in SEQ ID NO: 5, an adenine at position 9261 in SEQ ID NO: 5, a thymine at position 37592 in SEQ ID NO: 5, a guanine at position 10537 in SEQ ID NO: 7, a cytosine at position 25216 in SEQ ID NO: 7 and a thymine at position 119368 in SEQ ID NO: 7.

### Claim 17 (depends on 16)

The isolated nucleic acid of claim 16, which comprises an adenine at position 16727 in SEQ ID NO: 3.

### Claim 18 (depends on 16)

The isolated nucleic acid of claim 16, which comprises a polymorphic variation selected from the group consisting of a guanine at position 36589 in SEQ ID NO: 4, a thymine at position 44544 in SEQ ID NO: 4, a guanine at position 48304 in SEQ ID NO: 4.

### Claim 19 (depends on 16)

The isolated nucleic acid of claim 16, which comprises a polymorphic variation selected from the group consisting of a guanine at position 53843 in SEQ ID NO: 6, a guanine at position 63624 in SEQ ID NO: 6, an adenine-thymine deletion at position 65039 in SEQ ID NO: 6.

### Claim 20 (depends on 16)

The isolated nucleic acid of claim 16, which comprises a polymorphic variation selected from the group consisting of a guanine at position 206 in SEQ ID NO: 5, an adenine at position 9261 in SEQ ID NO: 5, a thymine at position 37592 in SEQ ID NO: 5.

### Claim 21 (depends on 16)

The isolated nucleic acid of claim 16, which comprises a polymorphic variation selected from the group consisting of a guanine at position 10537 in SEQ ID NO: 7, a cytosine at position 25216 in SEQ ID NO: 7 and a thymine at position 119368 in SEQ ID NO: 7.

### Claim 22 (depends on 16)

An oligonucleotide comprising a nucleotide sequence complementary to a portion of the nucleotide sequence of claim 16, wherein the 3′ end of the oligonucleotide is adjacent to a polymorphic variation.

### Claim 23 (depends on 16)

A microarray comprising an isolated nucleic acid of claim 16 linked to a solid support.

### Claim 24 (depends on 16)

An isolated polypeptide encoded by the isolated nucleic acid sequence of claim 16.

### Claim 25

A method of genotyping a nucleic acid at a position selected from the group consisting of position 16727 in SEQ ID NO: 3, position 36589 in SEQ ID NO: 4, position 44544 in SEQ ID NO: 4, position 48304 in SEQ ID NO: 4, position 53843 in SEQ ID NO: 6, position 63624 in SEQ ID NO: 6, position 65039 in SEQ ID NO: 6, position 206 in SEQ ID NO: 5, position 9261 in SEQ ID NO: 5, position 37592 in SEQ ID NO: 5, position 10537 in SEQ ID NO: 7, position 25216 in SEQ ID NO: 7 and position 119368 in SEQ ID NO: 7.

### Claim 26 (depends on 25)

The method of claim 25, which comprises genotyping the nucleic acid at position 16727 in SEQ ID NO: 3.

### Claim 27 (depends on 25)

The method of claim 25, which comprises genotyping the nucleic acid at a position selected from the group consisting of position 36589 in SEQ ID NO: 4, position 44544 in SEQ ID NO: 4 and position 48304 in SEQ ID NO: 4.

### Claim 28 (depends on 25)

The method of claim 25, which comprises genotyping the nucleic acid at a position selected from the group consisting of position 53843 in SEQ ID NO: 6, position 63624 in SEQ ID NO: 6 and position 65039 in SEQ ID NO: 6.

### Claim 29 (depends on 25)

The method of claim 25, which comprises genotyping the nucleic acid at a position selected from the group consisting of position 206 in SEQ ID NO: 5, position 9261 in SEQ ID NO: 5 and position 37592 in SEQ ID NO: 5.

### Claim 30 (depends on 25)

The method of claim 25, which comprises genotyping the nucleic acid at a position selected from the group consisting of position 10537 in SEQ ID NO: 7, position 25216 in SEQ ID NO: 7 and position 119368 in SEQ ID NO: 7.

### Claim 31

A method for identifying a candidate molecule that modulates cell proliferation, which comprises:
(a) introducing a test molecule to a system which comprises one or more cells and a a nucleic acid comprising one or more polymorphic variations at one or more positions selected from the group consisting of rs6481845, rs10643659, rs7475391, rs7475394, rs7475396, rs9418057, rs5784335, rs2429390, rs7209331, rs4968706, rs8072984, rs9896444, rs4968617, rs7350907, rs8072519, rs6467914, rs3064869, rs10555175, rs6956848, position 63624 in SEQ ID NO: 6, position 65039 in SEQ ID NO: 6, rs489941, rs496008, rs4650251, rs531412, rs3765654, rs6660350, position 206 in SEQ ID NO: 5, rs5924619, rs5924564, rs4828523, rs5924569, rs2052763, rs1549529, rs5924573, rs4240072, rs5924580, rs4828544, rs5969758, rs1965051, rs1426800, rs1365529, rs5924545, rs5969761, rs6629202, rs5924584, rs1365530, rs6527769, rs2382813, rs2033120, rs2162394, rs1346246, rs1365527, rs4828524, rs5924588, rs5969764, rs5924589, rs5924590, rs5924593, rs4828547, rs5969768, rs4828526, rs5924595, rs5924549, rs5969769, rs4007744, rs2891073, rs5924599, rs1549531, rs5924601, rs5901609, rs5969739, rs5924602, rs1426798, rs4828550, rs5924603, rs1807947, rs2382814, rs5924606 and position 25216 in SEQ ID NO: 7; and
(b) determining whether cell proliferation is increased or decreased compared to a system not containing the test molecule,
whereby a increased or decreased cell proliferation identifies the test molecule as a candidate molecule that modulates cell proliferation.

### Claim 32 (depends on 31)

The method of claim 31, wherein the system is an animal.

### Claim 33 (depends on 31)

The method of claim 31, wherein the system is one or more cells.

### Claim 34 (depends on 31)

A method for treating melanoma in a subject, which comprises administering a candidate molecule identified by the method of claim 31 to a subject in need thereof, whereby the candidate molecule treats melanoma in the subject.

### Claim 35

A method for treating melanoma in a subject or preventing melanoma in a subject, which comprises detecting the presence or absence of one or more polymorphic variations at one or more positions selected from the group consisting of rs6481845, rs10643659, rs7475391, rs7475394, rs7475396, rs9418057, rs5784335, rs2429390, rs7209331, rs4968706, rs8072984, rs9896444, rs4968617, rs7350907, rs8072519, rs6467914, rs3064869, rs10555175, rs6956848, position 63624 in SEQ ID NO: 6, position 65039 in SEQ ID NO: 6, rs489941, rs496008, rs4650251, rs531412, rs3765654, rs6660350, position 206 in SEQ ID NO: 5, rs5924619, rs5924564, rs4828523, rs5924569, rs2052763, rs1549529, rs5924573, rs4240072, rs5924580, rs4828544, rs5969758, rs1965051, rs1426800, rs1365529, rs5924545, rs5969761, rs6629202, rs5924584, rs1365530, rs6527769, rs2382813, rs2033120, rs2162394, rs1346246, rs1365527, rs4828524, rs5924588, rs5969764, rs5924589, rs5924590, rs5924593, rs4828547, rs5969768, rs4828526, rs5924595, rs5924549, rs5969769, rs4007744, rs2891073, rs5924599, rs1549531, rs5924601, rs5901609, rs5969739, rs5924602, rs1426798, rs4828550, rs5924603, rs1807947, rs2382814, rs5924606 and position 25216 in SEQ ID NO: 7; and
administering a melanoma treatment or administering a melanoma preventative to a subject in need thereof based upon the presence or absence of the one or more polymorphic variations in the nucleic acid sample.

### Claim 36 (depends on 35)

The method of claim 35, wherein the one or more polymorphic variations is at one or more positions selected from the group consisting of rs6481845, rs10643659, rs7475391, rs7475394, rs7475396, rs9418057 and rs5784335.

### Claim 37 (depends on 35)

The method of claim 35, wherein the one or more polymorphic variations is at one or more positions selected from the group consisting of rs2429390, rs7209331, rs4968706, rs8072984, rs9896444, rs4968617, rs7350907 and rs8072519.

### Claim 38 (depends on 35)

The method of claim 35, wherein a polymorphic variation is at position rs8404.

### Claim 39 (depends on 35)

The method of claim 35, wherein the one or more polymorphic variations is at one or more positions selected from the group consisting of rs6467914, rs3064869, rs10555175, rs6956848, position 63624 in SEQ ID NO: 6 and position 65039 in SEQ ID NO: 6.

### Claim 40 (depends on 35)

The method of claim 35, wherein the one or more polymorphic variations is at one or more positions selected from the group consisting of rs489941, rs496008, rs4650251, rs531412, rs3765654, rs6660350 and position 206 in SEQ ID NO: 5.

### Claim 41 (depends on 35)

The method of claim 35, wherein the one or more polymorphic variations is at one or more positions selected from the group consisting of rs5924619, rs5924564, rs4828523, rs5924569, rs2052763, rs1549529, rs5924573, rs4240072, rs5924580, rs4828544, rs5969758, rs1965051, rs1426800, rs1365529, rs5924545, rs5969761, rs6629202, rs5924584, rs1365530, rs6527769, rs2382813, rs2033120, rs2162394, rs1346246, rs1365527, rs4828524, rs5924588, rs5969764, rs5924589, rs5924590, rs5924593, rs4828547, rs5969768, rs4828526, rs5924595, rs5924549, rs5969769, rs4007744, rs2891073, rs5924599, rs1549531, rs5924601, rs5901609, rs5969739, rs5924602, rs1426798, rs4828550, rs5924603, rs1807947, rs2382814, rs5924606 and position 25216 in SEQ ID NO: 7.

### Claim 42 (depends on 35)

The method of claim 35, which further comprises extracting and analyzing a tissue biopsy sample from the subject.

### Claim 43 (depends on 35)

The method of claim 35, wherein the treatment is one or more selected from the group consisting of administering cisplatin, administering carmustine, administering vinblastine, administering vincristine, administering bleomycin, administering a combination of the foregoing, and surgery.

### Claim 44 (depends on 35)

The method of claim 35, wherein the preventative reduces ultraviolet (UV) light exposure to the subject.
